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ABCG2 Overexpression and
Deoxyadenosine Analogue
Activity in Acute Myeloid
Leukemia
We have read with great interest the article by Jabbour
et al1 entitled “A Randomized Phase 2 Study of Idarubicin
and Cytarabine With Clofarabine or Fludarabine in
Patients With Newly Diagnosed Acute Myeloid
Leukemia.” The authors reported that both clofarabine
and fludarabine were associated with high complete remis-
sion rates and a 2-year overall survival rate higher than
50% and that, in comparison with treatment with idaru-
bicin and cytarabine alone, fludarabine was associated
with superior outcomes for younger patients. Despite
these encouraging results, which are in line with what has
been achieved in other studies using these 2 purine nucle-
oside analogues2,3 or cladribine,4 disease relapse is still the
major cause of poor long-term outcomes for acute mye-
loid leukemia (AML) patients. Although disease-free sur-
vival is not clearly reported in Jabbour et al’s article, the
median event-free survival with both clofarabine and flu-
darabine is approximately 12 months.
Among the mechanisms of resistance of AML
blasts to anticancer therapy, the role of multidrug resis-
tance proteins is well established. In particular, the over-
expression of ATP-binding cassette subfamily G
member 2 (ABCG2) is associated with higher rates of
failure to achieve remission5 and shorter disease-free sur-
vival.6 We have previously reported that fludarabine-
based induction therapy does not overcome the negative
impact of high ABCG2 levels on disease-free survival.7
To investigate the possible influence of ABCG2 on clo-
farabine activity, we tested clofarabine toxicity in 3 dif-
ferent cell lines: RPMI8266 (overexpressing ABCG2),
A549 (heterozygous for the commonest amino acid vari-
ant in whites [Q141K] that alters protein function and
modifies sensitivity to many anticancer drugs),8 and
A498 (homozygous for the same polymorphism). HL60
(no ABC protein overexpression) and its ABCB1-
overexpressing subline HL60-DNR were used to assess
the effect of clofarabine in the presence of classic P-gly-
coprotein–mediated multidrug resistance. In parallel,
experiments in the same cellular settings were performed
with fludarabine.
Fludarabine fully overcame the negative effect of
ABCB1 overexpression (with inhibition dose 50 [ID50]
values of 30 and 24 ng/mL in HL60 and HL60-DNR, re-
spectively). An almost equal effect was obtained with clo-
farabine (with ID50 values of 14 and 7.5 ng/mL in HL60
and HL60-DNR, respectively). Completely different was
the impact of high levels of ABCG2 on the toxicity of the
2 drugs: in RPMI-8266, ID50 for fludarabine was 6000
ng/mL (ie, 200-fold higher than the value in HL60), and
this supports our previous observation of a worse progno-
sis for ABCG2-overexpressing AML patients treated with
fludarabine-based induction therapy. ID50 for clofarabine
in ABCG2-overexpressing cells (650 ng/mL) was lower
than the value for fludarabine but still almost 50 times
higher than the value for the negative control. With re-
spect to the ABCG2 polymorphism, no significant differ-
ences were observed for fludarabine, whereas in the
presence of the Q141K variant, both in homozygosity and
in heterozygosity, the negative impact on clofarabine was
nearly completely overcome.
In line with data published by Nagai et al,9 our find-
ings confirm a possible role of ABCG2 overexpression as a
cause of resistance to clofarabine, just as for fludarabine.
ABCG2 seems to be responsible for an increased rate of
AML relapse, maybe because of its expression in a blast
cell population with a stemlike phenotype that could con-
stitute a reservoir responsible for relapse.10 Deoxyadeno-
sine analogues are certainly effective drugs for AML when
they are used both in induction chemotherapy and in the
setting of relapsed or refractory disease,11 but various
mechanisms can be responsible for treatment failure. An
evaluation of ABCG2 expression should be considered
both at diagnosis and in the case of AML recurrence be-
cause ABCG2-negative patients could gain the maximal
benefit from clofarabine and fludarabine.
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Reply to ABCG2 Overexpression
and Deoxyadenosine Analogue
Activity in Acute Myeloid
Leukemia
We are grateful for the opportunity to respond to the let-
ter by Tiribelli et al regarding the potential role of drug ef-
flux pumps, particularly ATP-binding cassette subfamily
G member 2 (ABCG2; also known as BCRP), as mecha-
nisms of resistance in our study of clofarabine- or
fludarabine-based chemotherapy for patients with acute
myeloid leukemia (AML).1 Several authors have previous-
ly investigated the role of these pumps in resistance to
antileukemia therapy. These studies have varied in their
estimation of the proportion of newly diagnosed AML
patients with sufficiently high levels of ABCG2 expression
to cause resistance (values have ranged from 7% to 55%
according to the cutoff used).2,3 Nevertheless, these efflux
pumps have been correlated with worse outcomes in a
number of studies, including studies with patients who re-
ceived a fludarabine-based regimen.4,5 In their letter, Tiri-
belli et al present in vitro cell line data suggesting the
ABCG2 overexpression in AML blasts may mediate resis-
tance to both clofarabine and fludarabine. Given the
wealth of data showing that ABCG2 and other drug efflux
pumps play an integral role in AML resistance to cytotoxic
agents, we agree with them that such transporters certainly
may have mediated resistance for these nucleoside ana-
logue–based therapies in our study, at least in a subset of
patients in whom ABCG2 was overexpressed.
Because of the number of ways in which leukemic
cells are capable of developing resistance to chemotherapy,
this raises an important question about how these resis-
tance mechanisms can best be bypassed to improve the
outcomes of our patients with AML and other leukemias.
With the exception of younger patients with favorable-
risk disease features, there is likely a ceiling of benefit that
intensification of chemotherapy can achieve in AML.6
Perhaps for these younger patients who tend to have che-
mosensitive disease, an evaluation of drug efflux pump ex-
pression and strategies for targeting these transporters
may be beneficial. However, for the many patients with
AML who do not fit into this group (eg, older patients
and those with unfavorable cytogenetics or mutations),
novel agents and combination strategies are needed.
Improvements in AML outcomes will require con-
tinued molecular classification of AML to identify target-
able pathogenic mutations. For example, the addition of
FMS-like tyrosine kinase 3 (FLT3) inhibitors to chemo-
therapy has been shown to improve survival for patients
with FLT3–internal tandem duplication mutations.7 Sim-
ilarly, the promising results seen with isocitrate dehydro-
genase (IDH) inhibitors in the relapsed/refractory setting8
raise the question whether these agents should also be in-
corporated into frontline regimens for patients with IDH
mutations. Monoclonal antibodies conjugated with toxins
or bispecific antibody constructs (CD3 with CD33 or
CD123) may also provide effective anti-AML activity.9
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